Informatics software provider Dotmatics raises “significant investment”

Dotmatics, an informatics software and services provider, has raised “significant investment” after being backed by venture capital (VC) firm Scottish Equity Partners (SEP).

Founded in 2005 as a spin-out from a multinational pharmaceutical company, the business provides solutions for pharmaceutical, biotechnology, academia, food and beverage, oil and gas, and agrochemical industries.

Among its offering includes tools for knowledge management, data storage, enterprise querying and reporting, data analysis and visualisation.

The funding will enable Dotmatics to continue its investment into product innovation and customer success, as well as to strengthen operations in each of its key geographies.

Headquartered in Bishop’s Stortford, Dotmatics has two North American offices, one in China, one in Japan and another in South Korea.

It currently employs more than 100 people including chemists, biologists and software engineers across Europe, USA and Asia Pacific.

Established in 1991, SEP has traditionally focused on growth businesses but has also invested in early-stage companies with “outstanding potential”.

Based in Glasgow, with offices in London and Edinburgh, the VC normally makes equity investments of up to £20m in businesses operating within the health, science and tech sectors.

The investment deal was led by SEP partners Keith Davidson and Jan Rutherford.

Keith Davidson said:

“Dotmatics is a fast growing and capital efficient SaaS business, with an excellent reputation in the scientific research informatics market.

“The company has a strong focus on innovation and providing customers with first class scientific solutions and support.

“We have watched the company expand its customer base significantly over the course of the last few years and look forward to supporting its future growth plans.”

Stephen Gallagher, CEO of Dotmatics, said:

“We have grown rapidly and organically since inception and are pleased to have secured SEP as investors given the firm’s considerable software and health sector experience and their record of scaling companies.

“The funding will enable us to continue our aggressive trajectory in providing chemistry solutions, further expansion into biologics and increase our investment into customer support through strategic hires in application science product development and professional services.”